COMP <GO>
ASST vs JPM // REVENUE GROWTH (YOY)
Strive Inc. (NASDAQ) VS. JPMorgan Chase & Co. (NYSE) • 15-METRIC TALLY: ASST 4
— JPM 8
▲ REVENUE GROWTH (YOY) LEADER: ASST
LAST: $20.80 (-6.28%) • MKT CAP: $2.65B
revenue-growth
180.00%
LAST: $340.58 (+1.05%) • MKT CAP: $905.33B
revenue-growth
13.23%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ASST VS. JPM)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ASST | JPM | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 18.80% | 17.72% | +1.08 | ASST | /roic <GO> |
| EV/EBITDA & P/E Valuation | 19.7x | 9.5x | +10.20 | JPM | /valuation <GO> |
| Free Cash Flow Yield | 2.21% | -9.41% | +11.62 | ASST | /fcf-yield <GO> |
| Operating Margin | 13.90% | 41.98% | -28.08 | JPM | /operating-margins <GO> |
| Net Profit Margin | 10.90% | 32.48% | -21.58 | JPM | /net-margins <GO> |
| Revenue Growth (YoY) ACTIVE | 180.00% | 13.23% | +166.77 | ASST | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 1.95% | -1.95 | JPM | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | 0.37 | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 3/9 | +6.00 | ASST | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | 4.78% | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 36.4 | 53.6 | -17.20 | JPM | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.89 | 1.00 | -0.11 | JPM | /macro-sensitivity <GO> |
| Forward P/E Multiple | 27.6x | 13.3x | +14.33 | JPM | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $2.65B | $905.33B | -$902.68B | JPM | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ASST REV | JPM REV | ASST GROSS % | JPM GROSS % | ASST FCF | JPM FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $313.1M | $182.45B | — | — | $0 | -$147.78B |
| FY 2024 | $3.6M | $177.56B | — | — | -$21.6M | -$42.01B |
| FY 2023 | $277.0K | $158.10B | — | — | -$3.8M | $12.97B |
| FY 2022 | — | $128.69B | — | — | — | $107.12B |
| FY 2021 | — | $121.65B | — | — | — | $78.08B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ASST // BETA 0.89
JPM // BETA 1.00